nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—ADRA1B—vas deferens—urinary bladder cancer	0.212	0.589	CbGeAlD
Dextroamphetamine—TAAR1—female reproductive system—urinary bladder cancer	0.0302	0.0837	CbGeAlD
Dextroamphetamine—SLC18A2—prostate gland—urinary bladder cancer	0.0188	0.0521	CbGeAlD
Dextroamphetamine—CYP2D6—urine—urinary bladder cancer	0.0175	0.0485	CbGeAlD
Dextroamphetamine—ADRA1B—renal system—urinary bladder cancer	0.0129	0.0358	CbGeAlD
Dextroamphetamine—Aspartame—TRPV1—urinary bladder cancer	0.0114	0.388	CrCbGaD
Dextroamphetamine—ADRA1A—prostate gland—urinary bladder cancer	0.0106	0.0295	CbGeAlD
Dextroamphetamine—SLC18A2—female reproductive system—urinary bladder cancer	0.0102	0.0284	CbGeAlD
Dextroamphetamine—SLC18A2—vagina—urinary bladder cancer	0.00927	0.0257	CbGeAlD
Dextroamphetamine—ADRA1A—epithelium—urinary bladder cancer	0.00782	0.0217	CbGeAlD
Dextroamphetamine—ADRA1A—renal system—urinary bladder cancer	0.00726	0.0201	CbGeAlD
Dextroamphetamine—SLC18A2—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00709	0.0879	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—IL2—urinary bladder cancer	0.00704	0.239	CrCbGaD
Dextroamphetamine—Benzphetamine—POR—urinary bladder cancer	0.00627	0.213	CrCbGaD
Dextroamphetamine—SLC6A2—female reproductive system—urinary bladder cancer	0.00625	0.0174	CbGeAlD
Dextroamphetamine—SLC18A2—lymph node—urinary bladder cancer	0.00599	0.0166	CbGeAlD
Dextroamphetamine—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00521	0.0647	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00477	0.0592	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Dopaminergic Neurogenesis—GLI1—urinary bladder cancer	0.00429	0.0533	CbGpPWpGaD
Dextroamphetamine—CYP2D6—renal system—urinary bladder cancer	0.00427	0.0119	CbGeAlD
Dextroamphetamine—SLC6A3—Amine compound SLC transporters—SLC14A2—urinary bladder cancer	0.00423	0.0524	CbGpPWpGaD
Dextroamphetamine—SLC6A2—lymph node—urinary bladder cancer	0.00366	0.0101	CbGeAlD
Dextroamphetamine—CYP2D6—female reproductive system—urinary bladder cancer	0.00342	0.0095	CbGeAlD
Dextroamphetamine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00339	0.0421	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00284	0.0352	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00277	0.0344	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—urinary bladder cancer	0.00256	0.0318	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00241	0.0299	CbGpPWpGaD
Dextroamphetamine—Pseudoephedrine—TNF—urinary bladder cancer	0.00238	0.0807	CrCbGaD
Dextroamphetamine—Viral infection—Doxorubicin—urinary bladder cancer	0.00236	0.00446	CcSEcCtD
Dextroamphetamine—Nateglinide—PPARG—urinary bladder cancer	0.00233	0.0792	CrCbGaD
Dextroamphetamine—Agitation—Thiotepa—urinary bladder cancer	0.0023	0.00434	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00229	0.00432	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00228	0.00431	CcSEcCtD
Dextroamphetamine—Dyskinesia—Doxorubicin—urinary bladder cancer	0.00227	0.00429	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.00227	0.00428	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Etoposide—urinary bladder cancer	0.00226	0.00426	CcSEcCtD
Dextroamphetamine—Convulsion—Thiotepa—urinary bladder cancer	0.00217	0.00409	CcSEcCtD
Dextroamphetamine—Hypertension—Thiotepa—urinary bladder cancer	0.00216	0.00408	CcSEcCtD
Dextroamphetamine—Anxiety—Thiotepa—urinary bladder cancer	0.00212	0.00401	CcSEcCtD
Dextroamphetamine—Infection—Thiotepa—urinary bladder cancer	0.00203	0.00383	CcSEcCtD
Dextroamphetamine—Tachycardia—Thiotepa—urinary bladder cancer	0.00199	0.00376	CcSEcCtD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00195	0.0242	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Etoposide—urinary bladder cancer	0.00195	0.00369	CcSEcCtD
Dextroamphetamine—Anorexia—Thiotepa—urinary bladder cancer	0.00195	0.00368	CcSEcCtD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00187	0.0231	CbGpPWpGaD
Dextroamphetamine—Tremor—Cisplatin—urinary bladder cancer	0.00184	0.00347	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.00182	0.00345	CcSEcCtD
Dextroamphetamine—Hypertension—Gemcitabine—urinary bladder cancer	0.00182	0.00343	CcSEcCtD
Dextroamphetamine—Somnolence—Thiotepa—urinary bladder cancer	0.00182	0.00343	CcSEcCtD
Dextroamphetamine—Dyspepsia—Thiotepa—urinary bladder cancer	0.0018	0.0034	CcSEcCtD
Dextroamphetamine—Convulsion—Fluorouracil—urinary bladder cancer	0.00179	0.00339	CcSEcCtD
Dextroamphetamine—Chest pain—Gemcitabine—urinary bladder cancer	0.00179	0.00338	CcSEcCtD
Dextroamphetamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.00178	0.00335	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00176	0.00333	CcSEcCtD
Dextroamphetamine—Chest pain—Fluorouracil—urinary bladder cancer	0.00176	0.00333	CcSEcCtD
Dextroamphetamine—Fatigue—Thiotepa—urinary bladder cancer	0.00176	0.00333	CcSEcCtD
Dextroamphetamine—Constipation—Thiotepa—urinary bladder cancer	0.00175	0.0033	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00172	0.00324	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00171	0.00322	CcSEcCtD
Dextroamphetamine—Infection—Gemcitabine—urinary bladder cancer	0.00171	0.00322	CcSEcCtD
Dextroamphetamine—Irritability—Methotrexate—urinary bladder cancer	0.00171	0.00322	CcSEcCtD
Dextroamphetamine—Convulsion—Cisplatin—urinary bladder cancer	0.0017	0.00321	CcSEcCtD
Dextroamphetamine—Mood swings—Methotrexate—urinary bladder cancer	0.00169	0.0032	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00169	0.00319	CcSEcCtD
Dextroamphetamine—Infection—Fluorouracil—urinary bladder cancer	0.00168	0.00317	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00167	0.00315	CcSEcCtD
Dextroamphetamine—Anxiety—Cisplatin—urinary bladder cancer	0.00166	0.00314	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00166	0.00314	CcSEcCtD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.00165	0.0205	CbGpPWpGaD
Dextroamphetamine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00165	0.00311	CcSEcCtD
Dextroamphetamine—Affect lability—Epirubicin—urinary bladder cancer	0.00165	0.00311	CcSEcCtD
Dextroamphetamine—Anorexia—Gemcitabine—urinary bladder cancer	0.00164	0.00309	CcSEcCtD
Dextroamphetamine—Urticaria—Thiotepa—urinary bladder cancer	0.00162	0.00306	CcSEcCtD
Dextroamphetamine—Abdominal pain—Thiotepa—urinary bladder cancer	0.00161	0.00305	CcSEcCtD
Dextroamphetamine—Body temperature increased—Thiotepa—urinary bladder cancer	0.00161	0.00305	CcSEcCtD
Dextroamphetamine—Anorexia—Fluorouracil—urinary bladder cancer	0.00161	0.00304	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00161	0.00304	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.0016	0.00302	CcSEcCtD
Dextroamphetamine—Infection—Cisplatin—urinary bladder cancer	0.00159	0.003	CcSEcCtD
Dextroamphetamine—Mood swings—Epirubicin—urinary bladder cancer	0.00159	0.00299	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00158	0.00298	CcSEcCtD
Dextroamphetamine—Tachycardia—Cisplatin—urinary bladder cancer	0.00156	0.00295	CcSEcCtD
Dextroamphetamine—Convulsion—Etoposide—urinary bladder cancer	0.00156	0.00294	CcSEcCtD
Dextroamphetamine—Insomnia—Gemcitabine—urinary bladder cancer	0.00155	0.00293	CcSEcCtD
Dextroamphetamine—Hypertension—Etoposide—urinary bladder cancer	0.00155	0.00293	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00155	0.00292	CcSEcCtD
Dextroamphetamine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00153	0.00289	CcSEcCtD
Dextroamphetamine—Chest pain—Etoposide—urinary bladder cancer	0.00153	0.00289	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00153	0.00289	CcSEcCtD
Dextroamphetamine—Insomnia—Fluorouracil—urinary bladder cancer	0.00153	0.00289	CcSEcCtD
Dextroamphetamine—Somnolence—Gemcitabine—urinary bladder cancer	0.00153	0.00288	CcSEcCtD
Dextroamphetamine—Anorexia—Cisplatin—urinary bladder cancer	0.00153	0.00288	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—urinary bladder cancer	0.00152	0.00288	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00151	0.00285	CcSEcCtD
Dextroamphetamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00151	0.00284	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.0015	0.00284	CcSEcCtD
Dextroamphetamine—Somnolence—Fluorouracil—urinary bladder cancer	0.0015	0.00284	CcSEcCtD
Dextroamphetamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.00149	0.00282	CcSEcCtD
Dextroamphetamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00149	0.00281	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00148	0.0028	CcSEcCtD
Dextroamphetamine—Fatigue—Gemcitabine—urinary bladder cancer	0.00148	0.0028	CcSEcCtD
Dextroamphetamine—Constipation—Gemcitabine—urinary bladder cancer	0.00147	0.00277	CcSEcCtD
Dextroamphetamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00147	0.00277	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00147	0.00277	CcSEcCtD
Dextroamphetamine—Mood swings—Doxorubicin—urinary bladder cancer	0.00147	0.00277	CcSEcCtD
Dextroamphetamine—Asthenia—Thiotepa—urinary bladder cancer	0.00147	0.00277	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00146	0.00275	CcSEcCtD
Dextroamphetamine—Infection—Etoposide—urinary bladder cancer	0.00146	0.00275	CcSEcCtD
Dextroamphetamine—Tachycardia—Etoposide—urinary bladder cancer	0.00143	0.0027	CcSEcCtD
Dextroamphetamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00143	0.0027	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00142	0.00269	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00142	0.00268	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.00141	0.00267	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00141	0.00266	CcSEcCtD
Dextroamphetamine—Anorexia—Etoposide—urinary bladder cancer	0.0014	0.00264	CcSEcCtD
Dextroamphetamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.0014	0.00264	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00139	0.00263	CcSEcCtD
Dextroamphetamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.00139	0.00263	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00138	0.00261	CcSEcCtD
Dextroamphetamine—Depression—Methotrexate—urinary bladder cancer	0.00137	0.00259	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00137	0.00258	CcSEcCtD
Dextroamphetamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00136	0.00257	CcSEcCtD
Dextroamphetamine—Dizziness—Thiotepa—urinary bladder cancer	0.00135	0.00255	CcSEcCtD
Dextroamphetamine—Urticaria—Fluorouracil—urinary bladder cancer	0.00134	0.00253	CcSEcCtD
Dextroamphetamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00134	0.00252	CcSEcCtD
Dextroamphetamine—Sweating—Methotrexate—urinary bladder cancer	0.00132	0.00249	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00132	0.00249	CcSEcCtD
Dextroamphetamine—Weight decreased—Epirubicin—urinary bladder cancer	0.00131	0.00247	CcSEcCtD
Dextroamphetamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00131	0.00247	CcSEcCtD
Dextroamphetamine—Somnolence—Etoposide—urinary bladder cancer	0.0013	0.00246	CcSEcCtD
Dextroamphetamine—Vomiting—Thiotepa—urinary bladder cancer	0.0013	0.00245	CcSEcCtD
Dextroamphetamine—Rash—Thiotepa—urinary bladder cancer	0.00129	0.00243	CcSEcCtD
Dextroamphetamine—Dermatitis—Thiotepa—urinary bladder cancer	0.00129	0.00243	CcSEcCtD
Dextroamphetamine—Headache—Thiotepa—urinary bladder cancer	0.00128	0.00242	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00128	0.00241	CcSEcCtD
Dextroamphetamine—Decreased appetite—Etoposide—urinary bladder cancer	0.00128	0.00241	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00127	0.00239	CcSEcCtD
Dextroamphetamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00127	0.00239	CcSEcCtD
Dextroamphetamine—Fatigue—Etoposide—urinary bladder cancer	0.00127	0.00239	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.00126	0.0156	CbGpPWpGaD
Dextroamphetamine—Constipation—Etoposide—urinary bladder cancer	0.00125	0.00237	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00125	0.00237	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00124	0.00235	CcSEcCtD
Dextroamphetamine—Sweating—Epirubicin—urinary bladder cancer	0.00124	0.00233	CcSEcCtD
Dextroamphetamine—Asthenia—Gemcitabine—urinary bladder cancer	0.00123	0.00233	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00123	0.0153	CbGpPWpGaD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00122	0.00231	CcSEcCtD
Dextroamphetamine—Nausea—Thiotepa—urinary bladder cancer	0.00121	0.00229	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—urinary bladder cancer	0.00121	0.00229	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.0012	0.00227	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00118	0.00223	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00118	0.00223	CcSEcCtD
Dextroamphetamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00118	0.00222	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00117	0.00221	CcSEcCtD
Dextroamphetamine—Urticaria—Etoposide—urinary bladder cancer	0.00117	0.0022	CcSEcCtD
Dextroamphetamine—Abdominal pain—Etoposide—urinary bladder cancer	0.00116	0.00219	CcSEcCtD
Dextroamphetamine—Body temperature increased—Etoposide—urinary bladder cancer	0.00116	0.00219	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00116	0.00219	CcSEcCtD
Dextroamphetamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00116	0.00218	CcSEcCtD
Dextroamphetamine—Asthenia—Cisplatin—urinary bladder cancer	0.00115	0.00217	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—urinary bladder cancer	0.00114	0.00216	CcSEcCtD
Dextroamphetamine—Dizziness—Fluorouracil—urinary bladder cancer	0.00112	0.00211	CcSEcCtD
Dextroamphetamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.0011	0.00207	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00109	0.00207	CcSEcCtD
Dextroamphetamine—Vomiting—Gemcitabine—urinary bladder cancer	0.00109	0.00206	CcSEcCtD
Dextroamphetamine—SLC6A3—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00109	0.0135	CbGpPWpGaD
Dextroamphetamine—Rash—Gemcitabine—urinary bladder cancer	0.00108	0.00205	CcSEcCtD
Dextroamphetamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Dextroamphetamine—Headache—Gemcitabine—urinary bladder cancer	0.00108	0.00203	CcSEcCtD
Dextroamphetamine—Vomiting—Fluorouracil—urinary bladder cancer	0.00107	0.00203	CcSEcCtD
Dextroamphetamine—Rash—Fluorouracil—urinary bladder cancer	0.00107	0.00201	CcSEcCtD
Dextroamphetamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.00106	0.00201	CcSEcCtD
Dextroamphetamine—Headache—Fluorouracil—urinary bladder cancer	0.00106	0.002	CcSEcCtD
Dextroamphetamine—Asthenia—Etoposide—urinary bladder cancer	0.00105	0.00199	CcSEcCtD
Dextroamphetamine—Nausea—Gemcitabine—urinary bladder cancer	0.00102	0.00193	CcSEcCtD
Dextroamphetamine—Vomiting—Cisplatin—urinary bladder cancer	0.00102	0.00192	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00101	0.00191	CcSEcCtD
Dextroamphetamine—Rash—Cisplatin—urinary bladder cancer	0.00101	0.00191	CcSEcCtD
Dextroamphetamine—Dermatitis—Cisplatin—urinary bladder cancer	0.00101	0.00191	CcSEcCtD
Dextroamphetamine—Diarrhoea—Etoposide—urinary bladder cancer	0.001	0.0019	CcSEcCtD
Dextroamphetamine—Nausea—Fluorouracil—urinary bladder cancer	0.001	0.0019	CcSEcCtD
Dextroamphetamine—Tension—Epirubicin—urinary bladder cancer	0.000989	0.00187	CcSEcCtD
Dextroamphetamine—Nervousness—Epirubicin—urinary bladder cancer	0.000979	0.00185	CcSEcCtD
Dextroamphetamine—SLC6A3—Parkinsons Disease Pathway—CCNE1—urinary bladder cancer	0.000975	0.0121	CbGpPWpGaD
Dextroamphetamine—Dizziness—Etoposide—urinary bladder cancer	0.00097	0.00183	CcSEcCtD
Dextroamphetamine—Nausea—Cisplatin—urinary bladder cancer	0.000951	0.0018	CcSEcCtD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000936	0.0116	CbGpPWpGaD
Dextroamphetamine—Convulsion—Methotrexate—urinary bladder cancer	0.000933	0.00176	CcSEcCtD
Dextroamphetamine—Vomiting—Etoposide—urinary bladder cancer	0.000933	0.00176	CcSEcCtD
Dextroamphetamine—Agitation—Epirubicin—urinary bladder cancer	0.000926	0.00175	CcSEcCtD
Dextroamphetamine—Rash—Etoposide—urinary bladder cancer	0.000925	0.00175	CcSEcCtD
Dextroamphetamine—Dermatitis—Etoposide—urinary bladder cancer	0.000924	0.00175	CcSEcCtD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000924	0.0115	CbGpPWpGaD
Dextroamphetamine—Headache—Etoposide—urinary bladder cancer	0.000919	0.00174	CcSEcCtD
Dextroamphetamine—Chest pain—Methotrexate—urinary bladder cancer	0.000917	0.00173	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—urinary bladder cancer	0.000915	0.00173	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000906	0.00171	CcSEcCtD
Dextroamphetamine—Palpitations—Epirubicin—urinary bladder cancer	0.000891	0.00168	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000879	0.00166	CcSEcCtD
Dextroamphetamine—Convulsion—Epirubicin—urinary bladder cancer	0.000873	0.00165	CcSEcCtD
Dextroamphetamine—Infection—Methotrexate—urinary bladder cancer	0.000873	0.00165	CcSEcCtD
Dextroamphetamine—Nausea—Etoposide—urinary bladder cancer	0.000872	0.00165	CcSEcCtD
Dextroamphetamine—Hypertension—Epirubicin—urinary bladder cancer	0.00087	0.00164	CcSEcCtD
Dextroamphetamine—Chest pain—Epirubicin—urinary bladder cancer	0.000858	0.00162	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—urinary bladder cancer	0.000857	0.00162	CcSEcCtD
Dextroamphetamine—Anxiety—Epirubicin—urinary bladder cancer	0.000855	0.00161	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00085	0.0016	CcSEcCtD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000848	0.0105	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Epirubicin—urinary bladder cancer	0.000839	0.00158	CcSEcCtD
Dextroamphetamine—Anorexia—Methotrexate—urinary bladder cancer	0.000838	0.00158	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000824	0.00156	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000822	0.00155	CcSEcCtD
Dextroamphetamine—Infection—Epirubicin—urinary bladder cancer	0.000817	0.00154	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000808	0.00153	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000805	0.00152	CcSEcCtD
Dextroamphetamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000803	0.00152	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000795	0.0015	CcSEcCtD
Dextroamphetamine—Insomnia—Methotrexate—urinary bladder cancer	0.000795	0.0015	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—urinary bladder cancer	0.000794	0.0015	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000791	0.00149	CcSEcCtD
Dextroamphetamine—Anorexia—Epirubicin—urinary bladder cancer	0.000784	0.00148	CcSEcCtD
Dextroamphetamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000784	0.00148	CcSEcCtD
Dextroamphetamine—Somnolence—Methotrexate—urinary bladder cancer	0.000781	0.00148	CcSEcCtD
Dextroamphetamine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000776	0.00147	CcSEcCtD
Dextroamphetamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000774	0.00146	CcSEcCtD
Dextroamphetamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000764	0.00144	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000761	0.00144	CcSEcCtD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000759	0.00942	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000759	0.00143	CcSEcCtD
Dextroamphetamine—Fatigue—Methotrexate—urinary bladder cancer	0.000758	0.00143	CcSEcCtD
Dextroamphetamine—Infection—Doxorubicin—urinary bladder cancer	0.000756	0.00143	CcSEcCtD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000751	0.00932	CbGpPWpGaD
Dextroamphetamine—Insomnia—Epirubicin—urinary bladder cancer	0.000744	0.0014	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000743	0.0014	CcSEcCtD
Dextroamphetamine—ADRA1B—AMPK Signaling—TSC1—urinary bladder cancer	0.000738	0.00916	CbGpPWpGaD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000736	0.00139	CcSEcCtD
Dextroamphetamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000733	0.00138	CcSEcCtD
Dextroamphetamine—Somnolence—Epirubicin—urinary bladder cancer	0.000731	0.00138	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000725	0.00137	CcSEcCtD
Dextroamphetamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000724	0.00137	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000719	0.00136	CcSEcCtD
Dextroamphetamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000715	0.00135	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00071	0.00134	CcSEcCtD
Dextroamphetamine—Fatigue—Epirubicin—urinary bladder cancer	0.000709	0.00134	CcSEcCtD
Dextroamphetamine—Constipation—Epirubicin—urinary bladder cancer	0.000703	0.00133	CcSEcCtD
Dextroamphetamine—Urticaria—Methotrexate—urinary bladder cancer	0.000698	0.00132	CcSEcCtD
Dextroamphetamine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000695	0.00131	CcSEcCtD
Dextroamphetamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000695	0.00131	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—urinary bladder cancer	0.000688	0.0013	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000678	0.00128	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000677	0.00128	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000673	0.00127	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00067	0.00127	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000662	0.00125	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000657	0.00124	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000656	0.00124	CcSEcCtD
Dextroamphetamine—ADRA1A—AMPK Signaling—TSC1—urinary bladder cancer	0.000655	0.00813	CbGpPWpGaD
Dextroamphetamine—Urticaria—Epirubicin—urinary bladder cancer	0.000653	0.00123	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—urinary bladder cancer	0.000651	0.00123	CcSEcCtD
Dextroamphetamine—Abdominal pain—Epirubicin—urinary bladder cancer	0.00065	0.00123	CcSEcCtD
Dextroamphetamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.00065	0.00123	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000648	0.00122	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00064	0.00794	CbGpPWpGaD
Dextroamphetamine—Asthenia—Methotrexate—urinary bladder cancer	0.000631	0.00119	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000622	0.00118	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000606	0.00114	CcSEcCtD
Dextroamphetamine—Urticaria—Doxorubicin—urinary bladder cancer	0.000605	0.00114	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000602	0.00114	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000602	0.00114	CcSEcCtD
Dextroamphetamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000601	0.00114	CcSEcCtD
Dextroamphetamine—Asthenia—Epirubicin—urinary bladder cancer	0.00059	0.00111	CcSEcCtD
Dextroamphetamine—Dizziness—Methotrexate—urinary bladder cancer	0.000581	0.0011	CcSEcCtD
Dextroamphetamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000563	0.00106	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000561	0.00106	CcSEcCtD
Dextroamphetamine—Vomiting—Methotrexate—urinary bladder cancer	0.000559	0.00106	CcSEcCtD
Dextroamphetamine—Rash—Methotrexate—urinary bladder cancer	0.000554	0.00105	CcSEcCtD
Dextroamphetamine—Dermatitis—Methotrexate—urinary bladder cancer	0.000554	0.00105	CcSEcCtD
Dextroamphetamine—Headache—Methotrexate—urinary bladder cancer	0.000551	0.00104	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—urinary bladder cancer	0.000546	0.00103	CcSEcCtD
Dextroamphetamine—Dizziness—Epirubicin—urinary bladder cancer	0.000544	0.00103	CcSEcCtD
Dextroamphetamine—Vomiting—Epirubicin—urinary bladder cancer	0.000523	0.000988	CcSEcCtD
Dextroamphetamine—Nausea—Methotrexate—urinary bladder cancer	0.000522	0.000986	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000521	0.000983	CcSEcCtD
Dextroamphetamine—Rash—Epirubicin—urinary bladder cancer	0.000519	0.000979	CcSEcCtD
Dextroamphetamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000518	0.000978	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000516	0.00641	CbGpPWpGaD
Dextroamphetamine—Headache—Epirubicin—urinary bladder cancer	0.000515	0.000973	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000509	0.00632	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Alpha-synuclein signaling—SRC—urinary bladder cancer	0.000508	0.0063	CbGpPWpGaD
Dextroamphetamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000503	0.00095	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000489	0.00607	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000489	0.00607	CbGpPWpGaD
Dextroamphetamine—Nausea—Epirubicin—urinary bladder cancer	0.000489	0.000923	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000484	0.000914	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000483	0.00599	CbGpPWpGaD
Dextroamphetamine—Rash—Doxorubicin—urinary bladder cancer	0.00048	0.000906	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000479	0.000905	CcSEcCtD
Dextroamphetamine—Headache—Doxorubicin—urinary bladder cancer	0.000477	0.0009	CcSEcCtD
Dextroamphetamine—SLC6A2—NRF2 pathway—NQO1—urinary bladder cancer	0.000475	0.00589	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—urinary bladder cancer	0.000467	0.00579	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000463	0.00574	CbGpPWpGaD
Dextroamphetamine—Nausea—Doxorubicin—urinary bladder cancer	0.000452	0.000854	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000448	0.00555	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000442	0.00548	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000431	0.00534	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—NQO1—urinary bladder cancer	0.000421	0.00522	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—urinary bladder cancer	0.000413	0.00513	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000403	0.005	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000398	0.00493	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000396	0.00491	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000382	0.00473	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000377	0.00468	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000372	0.00462	CbGpPWpGaD
Dextroamphetamine—SLC6A2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000364	0.00452	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSTP1—urinary bladder cancer	0.000351	0.00435	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—RHOA—urinary bladder cancer	0.000338	0.0042	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.00033	0.00409	CbGpPWpGaD
Dextroamphetamine—SLC6A3—NRF2 pathway—GSTM1—urinary bladder cancer	0.000322	0.004	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GLI1—urinary bladder cancer	0.000312	0.00387	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000311	0.00386	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—RHOA—urinary bladder cancer	0.000298	0.0037	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—CXCL8—urinary bladder cancer	0.000297	0.00369	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000276	0.00342	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—MMP9—urinary bladder cancer	0.000269	0.00333	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000268	0.00333	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—RHOA—urinary bladder cancer	0.000265	0.00328	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000265	0.00328	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000255	0.00316	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000254	0.00315	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—CDKN1A—urinary bladder cancer	0.000252	0.00313	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000251	0.00312	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—SRC—urinary bladder cancer	0.000248	0.00307	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000225	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—CDKN1A—urinary bladder cancer	0.000224	0.00278	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—EGFR—urinary bladder cancer	0.000217	0.00269	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000214	0.00266	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RBX1—urinary bladder cancer	0.000214	0.00265	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000208	0.00258	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TSC1—urinary bladder cancer	0.000201	0.00249	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—JAG1—urinary bladder cancer	0.000191	0.00237	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—HRAS—urinary bladder cancer	0.000174	0.00216	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—urinary bladder cancer	0.000172	0.00213	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000171	0.00213	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000162	0.00201	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—S100B—urinary bladder cancer	0.000155	0.00192	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—urinary bladder cancer	0.000152	0.00189	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000152	0.00188	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—RHOA—urinary bladder cancer	0.000147	0.00182	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000144	0.00179	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000142	0.00176	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000142	0.00176	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NCOR1—urinary bladder cancer	0.000139	0.00173	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL2—urinary bladder cancer	0.000136	0.00168	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	0.000135	0.00167	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000132	0.00164	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000131	0.00162	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000129	0.0016	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL2—urinary bladder cancer	0.000123	0.00153	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TERT—urinary bladder cancer	0.000123	0.00152	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000119	0.00148	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FGFR3—urinary bladder cancer	0.000113	0.0014	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ESR1—urinary bladder cancer	0.000109	0.00136	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—HRAS—urinary bladder cancer	0.000103	0.00128	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CREBBP—urinary bladder cancer	9.59e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1—urinary bladder cancer	9.47e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EGFR—urinary bladder cancer	9.42e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HDAC4—urinary bladder cancer	9.41e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KRAS—urinary bladder cancer	8.9e-05	0.0011	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.83e-05	0.0011	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RHOA—urinary bladder cancer	8.67e-05	0.00108	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.37e-05	0.00104	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.37e-05	0.00104	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HDAC4—urinary bladder cancer	8.36e-05	0.00104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	8.34e-05	0.00104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	8.23e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	8.04e-05	0.000998	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB2—urinary bladder cancer	8.03e-05	0.000996	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.02e-05	0.000996	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GLI1—urinary bladder cancer	7.89e-05	0.000978	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	7.78e-05	0.000965	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.66e-05	0.00095	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL8—urinary bladder cancer	7.61e-05	0.000945	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—HRAS—urinary bladder cancer	7.56e-05	0.000938	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.41e-05	0.000919	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	7.31e-05	0.000907	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL2—urinary bladder cancer	7.28e-05	0.000903	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.11e-05	0.000882	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCND1—urinary bladder cancer	7.09e-05	0.00088	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GLI1—urinary bladder cancer	7e-05	0.000869	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	6.91e-05	0.000857	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.89e-05	0.000855	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MMP9—urinary bladder cancer	6.89e-05	0.000854	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.86e-05	0.000851	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTEN—urinary bladder cancer	6.85e-05	0.000849	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	6.61e-05	0.00082	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EP300—urinary bladder cancer	6.53e-05	0.00081	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.51e-05	0.000808	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL8—urinary bladder cancer	6.35e-05	0.000788	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SRC—urinary bladder cancer	6.35e-05	0.000788	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.34e-05	0.000787	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	6.16e-05	0.000765	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	5.87e-05	0.000729	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—urinary bladder cancer	5.69e-05	0.000706	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL8—urinary bladder cancer	5.64e-05	0.0007	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EGFR—urinary bladder cancer	5.56e-05	0.00069	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RBX1—urinary bladder cancer	5.4e-05	0.000671	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—urinary bladder cancer	5.26e-05	0.000652	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC1—urinary bladder cancer	5.08e-05	0.00063	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.07e-05	0.000629	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JAG1—urinary bladder cancer	4.84e-05	0.0006	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RBX1—urinary bladder cancer	4.8e-05	0.000596	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—urinary bladder cancer	4.67e-05	0.00058	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.59e-05	0.000569	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC1—urinary bladder cancer	4.51e-05	0.00056	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HRAS—urinary bladder cancer	4.47e-05	0.000554	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JAG1—urinary bladder cancer	4.3e-05	0.000533	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—RHOA—urinary bladder cancer	4.09e-05	0.000507	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.96e-05	0.000491	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—S100B—urinary bladder cancer	3.92e-05	0.000486	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RHOA—urinary bladder cancer	3.71e-05	0.000461	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.67e-05	0.000455	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.67e-05	0.000455	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—RHOA—urinary bladder cancer	3.63e-05	0.000451	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.59e-05	0.000445	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.56e-05	0.000441	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	3.52e-05	0.000437	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—S100B—urinary bladder cancer	3.48e-05	0.000432	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	3.43e-05	0.000426	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RHOA—urinary bladder cancer	3.3e-05	0.000409	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	3.26e-05	0.000404	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.19e-05	0.000396	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	3.13e-05	0.000388	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	3.12e-05	0.000387	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	3.1e-05	0.000385	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	3.05e-05	0.000378	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.96e-05	0.000367	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.9e-05	0.000359	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	2.85e-05	0.000353	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	2.77e-05	0.000343	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	2.77e-05	0.000343	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	2.76e-05	0.000342	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	2.53e-05	0.000314	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.47e-05	0.000306	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	2.46e-05	0.000305	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	2.42e-05	0.000301	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	2.39e-05	0.000297	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	2.38e-05	0.000296	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.29e-05	0.000284	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.27e-05	0.000281	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.27e-05	0.000281	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	2.25e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	2.19e-05	0.000272	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.17e-05	0.000269	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.15e-05	0.000267	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.13e-05	0.000264	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	2.13e-05	0.000264	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	2.12e-05	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.03e-05	0.000252	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2e-05	0.000248	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	2e-05	0.000248	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.95e-05	0.000242	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.93e-05	0.000239	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.91e-05	0.000237	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.84e-05	0.000228	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.8e-05	0.000224	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.79e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.74e-05	0.000216	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.74e-05	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.73e-05	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.71e-05	0.000212	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.7e-05	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.65e-05	0.000205	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.63e-05	0.000203	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.62e-05	0.000201	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	1.61e-05	0.000199	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.59e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.56e-05	0.000194	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.55e-05	0.000192	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.54e-05	0.000191	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.54e-05	0.000191	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.47e-05	0.000182	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.44e-05	0.000179	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.43e-05	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.41e-05	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.33e-05	0.000165	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.28e-05	0.000159	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.28e-05	0.000158	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.25e-05	0.000155	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	1.18e-05	0.000147	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.18e-05	0.000147	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	1.13e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.11e-05	0.000138	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.06e-05	0.000132	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	1.05e-05	0.00013	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	1e-05	0.000125	CbGpPWpGaD
